Zurzuvae Shortage: What Providers and Prescribers Need to Know in 2026

Since zuranolone (Zurzuvae) received FDA approval in August 2023, it has represented a genuinely new treatment modality for postpartum depression—the first FDA-approved oral PPD medication, and as of January 2025, the only FDA-approved PPD-specific agent remaining on the U.S. market following the voluntary withdrawal of brexanolone (Zulresso).

But many providers are finding that prescribing Zurzuvae is substantially more complex than typical antidepressant therapy. This briefing summarizes what you need to know in 2026: the access landscape, the specialty pharmacy workflow, payer navigation, and clinical decision-making when access is delayed.

Current Availability Status

Zurzuvae is

not on the FDA's official drug shortage list as of 2026. Supply from Sage Therapeutics and Biogen is not interrupted. However, it is a Limited Distribution Drug (LDD), available exclusively through an authorized specialty pharmacy network. This structural constraint—not a manufacturing issue—is the primary source of access challenges your patients report.

The Specialty Pharmacy Submission Workflow

Zurzuvae cannot be sent to a retail pharmacy. Your office must submit prescriptions directly to an authorized specialty pharmacy. The workflow is as follows:

1. Step 1: Verify which specialty pharmacies are in-network for your patient's insurance. Your patient's insurer or Sage Central (1-844-987-9882) can provide this information.
2. Step 2: Use the correct ICD-10 code: F53.0 (postpartum depression). Using the wrong code is one of the most common causes of prior authorization delay.
3. Step 3: Submit the prior authorization via CoverMyMeds or the health plan's specific PA form. Ensure all fields are complete before submission—incomplete forms are a frequent source of delay.
4. Step 4: The specialty pharmacy will contact your patient twice: once to verify insurance and contact information, and again after insurance approval to coordinate shipment.

Advise patients to add the specialty pharmacy number to their contacts—calls from unknown numbers are frequently missed or marked as spam.

Payer Landscape and Prior Authorization in 2026

Coverage has expanded significantly since 2023. Approximately 95% of patients with commercial insurance or Medicaid now have some level of coverage. The three largest PBMs include Zurzuvae on formulary. However, the tier placement, prior authorization requirements, and step therapy policies vary substantially by plan.

Step therapy: Some plans still require documented failure or contraindication to an SSRI before approving Zurzuvae. If your patient has already tried and failed an SSRI, document this clearly in the PA. For patients with severe PPD, consider explicitly documenting clinical urgency and the appropriateness of zuranolone's rapid mechanism.

Medicare: Typically Tier 5 on Part D formularies. The manufacturer savings card cannot be used for Medicare beneficiaries. Explore whether your patient qualifies for Low Income Subsidy (LIS/Extra Help) to reduce cost-sharing.

When to Offer a Bridge or Alternative Treatment

If the specialty pharmacy process or prior authorization is likely to take more than a few days, consider bridging with an SSRI (sertraline is the most evidence-supported for PPD) while continuing to pursue Zurzuvae authorization. Key clinical considerations:

• Zurzuvae can be used concurrently with SSRIs—in clinical trials, 15–21% of participants were on antidepressants at baseline
• Zurzuvae's fastest meaningful clinical benefit is its rapid onset—typically Day 3—which SSRIs cannot replicate
• For patients who are breastfeeding, note that Zurzuvae lacks safety data; sertraline and escitalopram are preferred in this setting
• For patients with suicidal ideation, active psychosis, or severe self-neglect, inpatient psychiatric evaluation is warranted regardless of medication access

38,440+ patients found their medications in stock

38K+

Find Zurzuvae In Stock Today →

Key Safety Reminders for Prescribers

When prescribing Zurzuvae, ensure you counsel patients on:

• Driving restriction: Patients must not drive or operate heavy machinery for at least 12 hours after each dose. This boxed warning is particularly relevant for mothers who drive their infants to appointments.
• Fetal harm / contraception: Patients must use effective contraception during the 14-day course and for one week after the final dose.
• CNS depressants: Co-administration with alcohol, opioids, benzodiazepines, or TCAs significantly increases CNS depression risk.
• CYP3A4 inhibitors: Reduce Zurzuvae dose for patients on strong CYP3A4 inhibitors (e.g., fluconazole, clarithromycin, ketoconazole).
• Suicidality monitoring: Monitor closely, particularly in the first weeks of treatment.

Resources for Providers

Sage Central: 1-844-987-9882 — Assistance with PA, specialty pharmacy routing, and patient savings enrollment. | medfinder for providers: medfinder.com/providers — A clinical tool to help identify specialty pharmacies able to fill your patients' Zurzuvae prescriptions.